Helix Biopharma Corp - ESG Rating & Company Profile powered by AI
Alternative corporations in the scoring industry group for Helix Biopharma Corp are displayed below. This webpage displays a free Sustainability assessment for Helix Biopharma Corp. This Disclosure score covers 17 UN SDGs including: 'Gender Equality', 'Responsible Production & Consumption' and 'Life below Water'.
Helix Biopharma Corp in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.2; made up of an environmental score of 5.3, social score of 3.2 and governance score of 4.0.
4.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 951 | Purple Biotech Ltd | 4.3 | High |
| 951 | Vectura Group Services Ltd | 4.3 | High |
| 969 | Helix Biopharma Corp | 4.2 | High |
| 969 | Botanix Pharmaceuticals Ltd | 4.2 | High |
| 969 | Arvinas Inc | 4.2 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Helix Biopharma Corp have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Helix Biopharma Corp disclose current and historical energy intensity?
Sign up for free to unlockDoes Helix Biopharma Corp report the average age of the workforce?
Sign up for free to unlockDoes Helix Biopharma Corp reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Helix Biopharma Corp disclose its ethnicity pay gap?
Sign up for free to unlockDoes Helix Biopharma Corp disclose cybersecurity risks?
Sign up for free to unlockDoes Helix Biopharma Corp offer flexible work?
Sign up for free to unlockDoes Helix Biopharma Corp have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Helix Biopharma Corp disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Helix Biopharma Corp conduct supply chain audits?
Sign up for free to unlockDoes Helix Biopharma Corp disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Helix Biopharma Corp conduct 360 degree staff reviews?
Sign up for free to unlockDoes Helix Biopharma Corp disclose the individual responsible for D&I?
Sign up for free to unlockDoes Helix Biopharma Corp disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Helix Biopharma Corp disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Helix Biopharma Corp disclose water use targets?
Sign up for free to unlockDoes Helix Biopharma Corp have careers partnerships with academic institutions?
Sign up for free to unlockDid Helix Biopharma Corp have a product recall in the last two years?
Sign up for free to unlockDoes Helix Biopharma Corp disclose incidents of discrimination?
Sign up for free to unlockDoes Helix Biopharma Corp allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Helix Biopharma Corp issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Helix Biopharma Corp disclose parental leave metrics?
Sign up for free to unlockDoes Helix Biopharma Corp disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Helix Biopharma Corp disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Helix Biopharma Corp disclose the pay ratio of women to men?
Sign up for free to unlockDoes Helix Biopharma Corp support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Helix Biopharma Corp disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Helix Biopharma Corp reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Helix Biopharma Corp involved in embryonic stem cell research?
Sign up for free to unlockDoes Helix Biopharma Corp disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Helix Biopharma Corp disclose its waste policy?
Sign up for free to unlockDoes Helix Biopharma Corp report according to TCFD requirements?
Sign up for free to unlockDoes Helix Biopharma Corp disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Helix Biopharma Corp disclose energy use targets?
Sign up for free to unlockDoes Helix Biopharma Corp disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Helix Biopharma Corp have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Helix Biopharma Corp
These potential risks are based on the size, segment and geographies of the company.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.